Acromegalic cardiomyopathy: a review of the literature

Area of Science:

• Cardiology
• Endocrinology
• Internal Medicine

Background:

• Acromegaly presents a high incidence of cardiovascular complications, contributing to elevated morbidity and mortality.
• Excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are implicated in the cardiac dysfunction observed in acromegaly.
• Hypertension, impaired glucose tolerance, and coronary artery disease are coexisting factors that may accelerate acromegalic cardiomyopathy progression.

Purpose of the Study:

• To review the key pathophysiological mechanisms underlying cardiovascular complications in acromegaly.
• To summarize the functional and morphological cardiac changes associated with acromegaly.
• To provide a comprehensive overview of acromegalic cardiomyopathy.

Main Methods:

• Literature review of relevant pathophysiological, functional, and morphological findings.
• Synthesis of data from existing studies on acromegaly and cardiovascular disease.
• Analysis of the role of GH and IGF-1 excess in cardiac dysfunction.

Main Results:

• Cardiovascular complications are a major concern in acromegaly, impacting patient outcomes.
• GH and IGF-1 excess directly contribute to cardiac abnormalities.
• Multiple comorbidities exacerbate the cardiac burden in acromegaly patients.

Conclusions:

• Acromegaly significantly increases the risk of cardiovascular disease.
• Understanding the interplay of GH/IGF-1 and comorbidities is crucial for managing acromegalic cardiomyopathy.
• Further research into targeted therapies for cardiac protection in acromegaly is warranted.